Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Adverse events · solid organ transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · solid organ transplant recipients
Maribavir showed no clear difference in adverse events compared with ganciclovir (moderate certainty).
1 finding from 1 review
Adverse events: hair loss · SSNS in children
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: all infections · SSNS in children
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review